ArticleFrontiers in pharmacology2026

Durable complete response to tislelizumab in advanced pMMR cervical cancer and successful rechallenge after immune-related NSTEMI: a case report.

Qingyun Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.